Skip to main content

Non-invasive Prenatal Testing Market to Reach USD 13.16 Billion by 2028; Technological Intervention to Play a Massive Role in Growth, says Fortune Business Insights™

Pune, India, April 26, 2021 (GLOBE NEWSWIRE) — The global non-invasive prenatal testing (NIPT) market size is projected to reach USD 13.16 billion by the end of 2028. The presence of several large scale companies will have a positive impact on the growth of the market in the upcoming years. According to a report published by Fortune Business Insights, titled, “Non Invasive Prenatal Testing (NIPT) Market, 2021-2028,” the market was worth USD 3.48 billion in 2020 and will exhibit a CAGR of 18.1% during the forecast period, 2021-2028.

Industry Developments:

July 2019: Invitae announced that it will be acquiring Singular Bio, a company specializing in single-molecule cell-free DNA analysis. The collaboration will be aimed at developing non-invasive prenatal tests.

Request a Sample Copy of the Research Report:

https://www.fortunebusinessinsights.com/enquiry/sample/non-invasive-prenatal-testing-market-100998

List of Non-invasive Prenatal Testing Providers Profiled in the Report:

  • Illumina, Inc.  (U.S.)
  • YOURGENE HEALTH (U.K.)
  • Natera   (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • PerkinElmer Inc. (U.S.)
  • Laboratory Corporation of America (U.S.)
  • Eurofins LifeCodexx GmbH (Germany)
  • Others

COVID-19 Pandemic to Have a Minimal Impact on NIPT Manufacturers

The COVID-19 pandemic has had an adverse effect on several industries across the world. Several reputed companies operating in the non-invasive prenatal testing industry are constantly keeping in touch with the U.S. FDA to get to know detailed information about supply chain disruptions. Also, research institutes are conducting many studies to determine the effect of the coronavirus on births and pregnancies. SeraCare’s report, for instance, declares that clinical testing laboratories and in-vitro diagnostics manufacturers are working closely to determine the interference of SARS-CoV-2 infection on childbirths.

To get to know more about the short-term and long-term impact of COVID-19 on this market, please visit: https://www.fortunebusinessinsights.com/industry-reports/non-invasive-prenatal-testing-market-100998

NGS Segment Held 77.8% Share in 2020, reports Fortune Business Insights

Based on the product, the market is categorized into instruments and consumables & reagents. By end-users, it is bifurcated into clinical laboratories and hospitals. Lastly, based on the technology, it is divided into rolling circular amplification, PCR, microarray, and NGS. Out of these, the NGS segment generated 77.8% in terms of the non-invasive prenatal testing market share in 2020. It is anticipated to remain at the forefront stoked by its usage in a wide range of applications, especially for analyzing the risk of foetal chromosomal anomalies.

Report Coverage-

This research report includes in-depth information about the Non Invasive Prenatal Testing industry. The data present in it is related to drastic changes in material usage, unique product launches, and technological advancements. It offers dynamics based on various factors, such as opportunities, challenges, drivers, and restraints. In addition to that, it will deliver a complete insight from the supply side respondents related to market share, distribution, and size.

Quick Buy –  Non-Invasive Prenatal Testing Market Research Report:

https://www.fortunebusinessinsights.com/checkout-page/100998

Rising Number of Company Mergers and Acquisitions to Have a Huge Impact on Market Growth

The report encompasses several factors that have contributed to the growth of the overall market in recent years. Amongst them, the increasing number of company collaborations has made the highest impact on the market growth. In March 2019, for instance, Natera announced that it has formed a strategic partnership with QIAGEN. Through this collaboration, the company will develop breakthrough cell-free DNA assays. These companies will further capitalize on QIAGEN’s GeneReader NGS System.

Such collaborations are aimed at advancing in the NIPT sector and more companies will look to maximize the use of technologically advanced concepts. Natera’s collaboration with QIAGEN is among the major company collaborations of recent times that have had a major say on the growth of the non-invasive prenatal testing market.

North America to Emerge Dominant; Presence of Several Diagnostic Centres to Aid Growth

The report analyses the ongoing market trends across five major regions, including North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Among all regions, the market in North America is projected to emerge dominant in the upcoming years.  The increasing penetration of non-invasive prenatal testing will bode well for the growth of the regional market. The increasing incidence of Down syndrome among babies, especially in the United States will have a massive impact on the growth of the regional market. The rising investments in the research and development of efficient NIPT by large scale companies in this region will emerge in favor of market growth. As of 2020, the market in North America was worth USD 1.79 billion and this value is projected to increase further in the forthcoming years.

Have Any Query? Ask Our Experts:

https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/non-invasive-prenatal-testing-market-100998

Key Players Aim to Develop New Tests to Cater to High Consumer Demand Worldwide

The market for non-invasive prenatal testing is highly consolidated with the presence of numerous companies. Most of them are participating in the strategy of partnerships and acquisitions to cater to the increasing demand from consumers. Some of the others are trying to conduct extensive R&D activities to unveil new technologies in the field of non-invasive prenatal testing.

Table Of Contents :

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Key Insights
    • Technological Advancements in Non-Invasive Prenatal Testing (NIPT) Techniques
    • Number of NIPT Tests Performed, Key Regions, 2019
    • Impact of COVID-19 on Non-Invasive Prenatal Testing Market
    • Key Industry Developments – Mergers, Acquisitions, Etc.
  • Global Non-Invasive Prenatal Testing (NIPT) Market Analysis, Insights and Forecast, 2017-2028
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Product
      • Consumables & Reagents
      • Instruments
    • Market Analysis, Insights and Forecast – By Technology
      • Next Generation Sequencing (NGS)
      • Microarray
      • Polymerase Chain Reaction (PCR)
      • Rolling Circular Amplification
    • Market Analysis, Insights and Forecast – By End User
      • Hospitals
      • Diagnostic Laboratories
    • Market Analysis, Insights and Forecast – By Region
      • North America
      • Europe
      • Asia pacific
      • Latin America
      • Middle East & Africa
  • North America Non-Invasive Prenatal Testing (NIPT) Market Analysis, Insights and Forecast, 2017-2028
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Product
      • Consumables & Reagents
      • Instruments
    • Market Analysis, Insights and Forecast – By Technology
      • Next Generation Sequencing (NGS)
      • Microarray
      • Polymerase Chain Reaction (PCR)
      • Rolling Circular Amplification
    • Market Analysis, Insights and Forecast – By End User
      • Hospitals
      • Diagnostic Laboratories
    • Market Analysis, Insights and Forecast – By Country
      •  U.S.
        • Consumables & Reagents
        • Instruments
      •  Canada
        • Consumables & Reagents
        • Instruments

Toc Continue..

Get your Customized Research Report:  https://www.fortunebusinessinsights.com/enquiry/customization/non-invasive-prenatal-testing-market-100998

SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:

  • Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companies
  • Details in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc.
  • Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facility
  • Number of procedures and average price of procedures
  • Replacement rate and pricing of capital equipment
  • Market dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunities
  • Market & technological trends, new product developments, product pipeline.

Have a Look at Related Reports:

Heparin Market Size, Share & COVID-19 Impact Analysis, By Product Type (Unfractionated Heparin (UFH), and Low Molecular Weight Heparin (LMWH)), By Source , By Application (Deep Vein Thrombosis & Pulmonary Embolism, Atrial Fibrillation, Heart Attacks, Stroke, and Others), By Route of Administration, By End User , and Regional Forecast, 2020-2027

Arthroscopy Fluid Management Disposables Market Size, Share & COVID-19 Impact Analysis, By Product (Pump Management Disposables and Gravity Management Disposables), By Application (Hospitals, Medical Centers, and Others) and Regional Forecast, 2020-2027

Liver Cancer Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Therapy Type (Targeted Drug Therapy, Immunotherapy, and Chemotherapy), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027

Immunomodulators Market Size, Share & COVID-19 Impact Analysis, By Product Type (Immunosuppressant, Immunostimulants), By Application (Oncology, Respiratory, Multiple Sclerosis, and Others), and Regional Forecast, 2020-2027

Medical X-ray Market Size, Share & Covid-19 Impact Analysis, By Product Type (Static and Dynamic), By Technology Type (Analog and Digital), By Application (Dental, Veterinary, Cardiovascular Oncology, and Others), By End-User (Hospitals & Clinics, Diagnostic Centers, and Others), and Regional Forecast, 2021-2028

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/global-non-invasive-prenatal-testing-market-10207

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.